Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Time to give UK PLC a break

Mon, 20th Jul 2020 12:15

* European stocks slightly up

* EU talks in focus

* Italy's UBI surges after Intesa raises bid by 18%
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts Joice Alves (joice.alves@thomsonreuters.com) and
Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

TIME TO GIVE UK PLC A BREAK (1115 GMT)

There hasn't been much love for shares in UK PLC since, well... quite some time now.
Remember that Brexit referendum way back in 2016?

As JPM analysts recall in their latest global strategy note, the "UK has now lagged global
peers in each of the last 5 years, as well as ytd, and this underperformance is not just due to
the strong U.S. run".

Nope, as they stress, the "UK has lost out vs the rest of Europe by a cumulative 25% over
that timeframe".

As we speak, the FTSE 100 is the top underperformer in Europe today as investors wait for EU
leaders to deliver a deal on their stimulus plan.

With hard Brexit fears still running high and a somewhat underwhelming response to the
COVID-19 pandemic, this wouldn't look like the perfect moment for a change of heart but JPM
analysts believe it's time to give UK PLC a break.

"We now believe that the relative risk-reward for UK is finally starting to improve, and are
closing our UW", they announced this morning, noting how cheap UK shares are trading and how the
dividend fallout is less of an issue now that the dust is settling on pay-outs.

JPM analysts say however that they are not convinced the British stock market has yet become
a value trade but they identified interesting sectors such as homebuilders and utilities.

If the pound remains weak, mining, pharma, staples and tech could also prove good
investments.

Here are two charts from the report showing the underperformance of UK PLC and how cheap it
is trading:

(Julien Ponthus)

*****

IS BIG CASH FROM CENTRAL BANKS PROLONGING THE CRISIS? (1024 GMT)

Food for thought: could it be that the trillions central banks poured at struggling
economies are actually prolonging the time it will take for companies to bounce back from the
COVID-19 depths?

So seems to believe Swiss asset manager Pictet.

“Unless these interventions return economies to robust health, they won’t have eradicated
the corporate sector’s underlying vulnerabilities. They are merely distorting the market and
prolonging the time it will take companies to return to health," Pictet writes in a note.

In this scenario, the asset manager expects distressed investments to be booming.

"The vast gap between corporate fundamentals and the price at which companies’ bonds and
stocks trade" is opening big "opportunities for distressed debt and special situations investors
since at least the global financial crisis," Pictet says.

"It is when the economic clouds darken that distressed securities prove their worth."

(Joice Alves)

*****

TECH, HEALTHCARE, PLEASE WELCOME CHEMICALS AND UTILITIES (1010 GMT)

Very few sectors had managed to recover from the March financial crash and make their way to
positive territory so far in 2020.

Healthcare and Tech have been one of the only safe havens in European equities for investors
to weather through the Covid-19 storm during the first half of 2020.

H2 seems a bit different on that front now with utilities and chemicals turning positive
year-on-year in July as you can see below.

That chemicals is pulling off a 2% rise is certainly a good omen for the bulls.

That being said, the STOXX 600 is still 10% down and as you can see on the table below the
chart, not a lot of sectors are even close to the floatation mark.

(Julien Ponthus)

*****

OPENING SNAPSHOT: RISK-OFF ON "MISSION IMPOSSIBLE" (0739 GMT)

European stock markets are clearly not feeling that optimistic on the chances of EU leaders
striking a deal today on what European Council President Charles Michel called "mission
impossible".

With healthcare being the only sector up and tech just barely hanging in there, it's clearly
risk off with the STOXX 600 down 0.7% and all European bourses in the red.

It's interesting to note that the euro is still up, which seems to indicate that there's
still some optimism on trading floors, just not for stocks.

The euro upbeat tone isn't helping euro zone banks. They're usually a bit of a proxy on EU
resilience and they are down 1.3%.

Of course, Natixis, which is losing close to 5% after its parent BPCE denied a buyback,
isn't helping. Julius Baer falling over 5% on its results also calls for some caution but then
gain, UBI Banca jumping 11% after Intesa raised its offer could have compensated somewhat.

Overall, the mood for banks in Europe just isn't positive.

But it's not only banks, other cyclical sector are deep in the red like Traval and Leisure,
down 2%.

Cruise operator Carnival, TUI, ICAG and Lufthansa are down all 5-3%.

There's some good news on the Q2 season front though with Philips, up more than 3%, seeing a
strong rebound in consumer demand in Europe during the second quarter as lockdowns were relaxed.

(Julien Ponthus)

*****

ON THE RADAR: JULIUS BAER, PHILIPS, M&S, HOMEBUILDERS (0651 GMT)

With EU leaders still negotiating terms of the recovery fund after three days of haggling
over a plan to revive economies, futures are pointing to a broadly flat open for European
bourses.

On the corporate front, active client trading during the pandemic helped Julius Baer
post a 43% rise in half-year net profit to 491 million Swiss francs ($523.01 million)
on Monday, a record result for the Swiss wealth manager.

Dutch health technology company Philips expects to return to growth in the second
half of the year, if hospitals and consumers were able to gradually overcome the first shock of
the pandemic.

Vaccine plans: Britain signs deals to secure 90 million doses of two possible COVID-19
vaccines from the Pfizer and BioNTech alliance and French group Valneva
. Meantime, UK company GSK plans to invest 130 million pounds ($163 million) in
German biotech firm CureVac for a 10% stake to work together on a novel type of vaccine.

And more reports on job cuts: British retailer Marks and Spencer Group Plc plans to
announce hundreds of job cuts in the coming week, Sky News reported on Sunday, citing sources.
Ted baker to cut 25% of its UK work force.

Eyes on homebuilders after British property website Rightmove said a mini housing market
boom was gathering pace after a tax cut by finance minister Rishi Sunak.

Shares of auction website Allegro seen up 20% by one trader, on owners' Warsaw listing plans
in September.

Airbus Signs contract with UK Ministry Of Defence for Skynet 6A Satellite.

(Joice Alves)

*****

MORNING CALL: EU STIMULUS CLIFF-HANGER (0530 GMT)

Who would have thought? EU summits often drag on for days but this is close to
unprecedented!

Among all the scenarios for which investors had prepared themselves for, one where EU
leaders would still be negotiating the stimulus package as markets opened on Monday morning was
clearly an unlikely one!

Anyhow, there it is: progress is being made after three days of haggling but Dutch Prime
Minister Mark Rutte has warned the discussions could still fall apart.

Forex traders seem more optimistic than stock investors at this stage: the euro is trading
at a handsome $1.4390, close to a four-month high while stock futures are broadly flat.

This cliff-hanger is going to be a long one with the meeting was adjourned until 1400 GMT.

(Julien Ponthus)

*****

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.